Presented by Dr. Sebastian Uhrig, German Cancer Research Center The MASTER (Molecularly Aided Stratification for Tumour ERadication) program is a precision oncology trial for patients with advanced-stage disease. The trial recruits patients of young age or suffering from rare cancer types. Multi-omics assays are used to create a molecular profile of the tumors with the goal of finding genetic aberrations which can be exploited therapeutically. Gene fusions play an important role in this setting, since many of the soft-tissue sarcomas which are part of the MASTER cohort are associated with oncogenic driver fusions. Often, the detection of a pathognomonic fusion serves to confirm or refine the diagnosis of a patient. More importantly, many fusions are recognized as potent drug targets and are therefore of central interest to the program. Furthermore, the multi-layered, in-depth analysis of each patient recruited in the MASTER trial has repeatedly revealed novel insights into the biology of cancer. After careful study and experimental validation in the context of basic cancer research projects, such findings can ultimately be translated into clinical practice.